A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by stimulating the mother’s body’s defences to generate defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with immediate protection from the point of delivery, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when immunised 4 weeks before birth
- Antibodies from the mother transferred through placenta safeguard newborns from birth
- Coverage possible with two-week gap before early delivery
- Vaccination during the third trimester still offers significant protection for infants
Persuasive evidence from recent research
The performance of the pregnancy RSV vaccine has been confirmed through a comprehensive study conducted across England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month period, providing robust and representative data of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scale of this research provides healthcare professionals and parents-to-be with assurance in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results reveal a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the vast majority being infants whose mothers did not receive the vaccination. This marked difference highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Methodology and scope of study
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and representative of the broader population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology measured real-world outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine works when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its threats
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe properly. Parents commonly see their babies struggling visibly, their chests rising whilst they try to pull sufficient oxygen into their compromised lungs. Whilst most newborns improve through palliative treatment, a modest yet notable proportion perish from RSV-related complications each year, making vaccination as prevention a critical public health objective for safeguarding the youngest and most vulnerable people in our communities.
- RSV causes inflammation in lungs, causing serious respiratory problems in babies
- Approximately half of infants contract the infection in their first few months of life
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV each year
- Few babies succumb to RSV related complications annually in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery offers nearly 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies via the placenta.
The communication from health authorities stays clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These regional differences demonstrate differences across medical facilities, engagement approaches, and local engagement efforts, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts rolling out diverse outreach initiatives to connect with expectant mothers
- Geographic variations in vaccine uptake rates across England necessitate strategic intervention
- Local healthcare systems adapting programmes to align with specific population needs
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness translates into real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this protective measure, the 80% drop in admissions equates to thousands of infants shielded from critical disease. Parents no longer face the distressing scenario of seeing their babies gasping for air or labour to feed, symptoms that define severe RSV infections. The vaccine has fundamentally shifted the picture of neonatal breathing health, offering expectant mothers a active means to shield their youngest infants during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab highlights the profound consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to pregnant women during their late pregnancy, converting what was once an predictable seasonal threat into a manageable health risk.